PUBLIC COMMUNICATION - Health Canada Endorsed Important Safety Information on Erythropoiesis-Stimulating Agents (ESAs): Aranesp(R) (darbepoetin alfa) and EPREX* (epoetin alfa)



    Subject: Important Safety Information and New Prescribing Information for
    the Erythropoiesis-Stimulating Agents, Aranesp(R) (darbepoetin alfa) and
    EPREX(*) (epoetin alfa)

    TORONTO, April 19 /CNW/ - The manufacturers of the
erythropoiesis-stimulating agents (ESAs), in consultation with Health Canada,
would like to inform you of updated safety information and pending label
changes regarding treatment with ESAs. Two ESAs, Aranesp(R) and EPREX, are
authorized for use in Canada. ESAs are drugs used to increase the production
of red blood cells and decrease the need for red blood cell transfusion. These
medicines may be used in patients with kidney failure or in patients with
cancer where the anemia is associated with chemotherapy.
    As a result of these updates, EPREX is no longer approved for use in
patients with cancer who do not have anemia associated with chemotherapy.
Therefore, none of the ESAs are approved for use in this patient population.
    In consultation with Health Canada, the Canadian prescribing information
for these medicines will be revised by the manufacturers to reflect the new
safety information listed in the box below. Patients are advised to contact
their doctor or pharmacist if they have any questions or concerns regarding
their current treatment with these medicines.

    
    -------------------------------------------------------------------------
    -   ESAs are drugs used to increase the production of red blood cells and
        to decrease the need for red blood cell transfusion and the dose
        should be gradually adjusted to achieve this goal. Hemoglobin levels
        during ESA treatment should not be higher than 120 g/L. (May not be
        applicable to all surgery patients, see below).

    -   Patients treated with EPREX before elective surgery should receive
        antithrombotic treatment to avoid blood clots.

    -   In recent studies, a higher risk of death and serious cardiovascular
        adverse events, such as stroke, heart attack, heart failure and blood
        clots was seen in both cancer and chronic kidney disease patients
        receiving ESAs to maintain a target hemoglobin level higher than
        120 g/L.

    -   A higher risk of death was seen in patients with cancer and anemia
        who were not receiving either radiation or chemotherapy and receiving
        ESAs to maintain a target hemoglobin level of 120 g/L. ESAs are not
        authorized for use in this patient population.

    -   Progression of tumour growth in patients with head and neck cancer
        receiving radiation therapy only, occurred sooner in patients who
        were also being treated with ESAs to a target hemoglobin level of
        greater than 120 g/L.

    -   Increased death was seen in patients with metastatic breast cancer
        receiving chemotherapy, who were also being treated with ESAs to a
        target hemoglobin level of greater than 120 g/L.
    -------------------------------------------------------------------------
    

    Several new medical studies, have described new risks associated with the
use of ESAs. These risks include cardiovascular problems, such as heart
attack, heart failure, stroke, blood clots or death, as well as decreased
survival in patients with cancer due to worsening of their cancer. ESAs are
not authorized for use in patients with cancer who do not have anemia
associated with chemotherapy. All patients should be monitored to ensure that
their red blood cell levels do not exceed 120 g/L while on ESA therapy.

    
    Signs and symptoms of serious cardiovascular events may include, but are
not limited to:

    -   chest pain
    -   leg pain and swelling
    -   shortness of breath
    -   sudden weakness, numbing or tingling of face, arm or leg
    -   severe sudden headache, loss of vision, or loss of speech
    

    Patients experiencing these signs or symptoms should contact their doctor
immediately. Patients should NOT discontinue their medication without
consulting their doctor first.

    A copy of the Health Care Professional letter and this communication are
available on the Health Canada website
(http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/index_e.html).
This information is also available at http://www.janssen-ortho.com.
    Managing marketed health product-related adverse reactions depends on
health care professionals and consumers reporting them. Reporting rates
determined on the basis of spontaneously reported post-marketing adverse
reactions are generally presumed to underestimate the risks associated with
health product treatments. Any case of heart attack, heart failure, stroke or
blood clots or other serious or unexpected adverse reactions in patients
receiving Aranesp(R) or EPREX should be reported to Amgen Canada (for
Aranesp(R)), Janssen-Ortho Inc (for EPREX) or Health Canada at the following
addresses:

    -------------------------------------------------------------------------
    Aranesp(R)

    Amgen Canada, Inc.
    6755 Mississauga Road, Suite 400
    Mississauga, Ontario L5N 7Y2
    Tel: (866) 502-6436
    Fax: (888) 264-3655
    safetycanada@amgen.com

    EPREX

    Janssen-Ortho Inc.
    19 Green Belt Drive
    Toronto, ON M3C 1L9
    Tel: (800) 567-3331
    Fax: (866) 767-5865
    dsscan@joica.jnj.com

    Any suspected adverse reaction can also be reported to:

    Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
    Marketed Health Products Directorate
    HEALTH CANADA
    Address Locator: 0701C
    OTTAWA, Ontario, K1A 0K9
    Tel: (613) 957-0337 or Fax: (613) 957-0335
    To report an Adverse Reaction, consumers and health professionals may
    call toll free:
    Tel: 866 234-2345
    Fax: 866 678-6789
    cadrmp@hc-sc.gc.ca

    The AR Reporting Form and the AR Guidelines can be found on the Health
    Canada web site or in The Canadian Compendium of Pharmaceuticals and
    Specialties.

    http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/form/ar-  
ei_form_e.html
    http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/guide/ar-ei_guid
e-ldir_e.html

    For other inquiries related to this communication, please contact Health
    Canada at:

    Marketed Health Products Directorate (MHPD)
    E-mail: mhpd_dpsc@hc-sc.gc.ca
    Tel: (613) 954-6522
    Fax: (613) 952-7738

    -------------------------------------------------------------------------

    
    Sincerely,

    (signed)                             (signed)

    David N. Churchill, MD, FRCPC        Cathy Lau, PhD.
    Medical Director, Nephrology         Vice President
    AMGEN Canada Inc.                    Regulatory and Quality
                                         Janssen-Ortho Inc.
    


    (*) All trademark rights used under license.





For further information:

For further information: For media enquiries, please contact: Natasha
Bond, Amgen Canada Inc., (905) 285-3007; Suzanne Frost, Janssen-Ortho Inc.,
(416) 449-9444; For Additional Information, please contact: Amgen Canada
Medical Information Department, 1-866-50AMGEN, from 9 a.m. to 5 p.m., Monday
to Friday, EST; Janssen-Ortho Medical Information Department, 1-800-567-3331,
from 8:30 a.m. to 4:30 p.m., Monday to Friday, EST

Organization Profile

JANSSEN-ORTHO INC.

More on this organization

Amgen Canada Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890